Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke
CEO and MD, Steven Yatomi Clarke
Source: Prescient Therapeutics
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Prescient Therapeutics (PTX) advanced its clinical programs during the June quarter
  • The oncology company completed the second cohort for its phase 1b study of its PTX-200 therapy and is now progressing to a higher dose level
  • Prescient also partnered with the Peter MacCallum Cancer Centre to advance its CAR-T therapy using the OmniCAR platform
  • Prescient spent $1.14 million on operating activities and wrapped up the quarter with just under $16.1 million in cash
  • Company shares are up 5.56 per cent and trading at 19 cents

Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter.

The clinical-stage oncology company focussed on driving multiple cancer programs for its PTX-100 and PTX-200 targeted therapies.

In April, the company successfully completed the second cohort for its phase 1b clinical study of PTX-100 and cytarabine in patients with acute myeloid leukemia (AML).

This cohort was dosed with 35 milligrams per square metre (mg/m2) and didn’t observe any safety or toxicity issues. This study is now progressing its higher dose level of 45 mg/m2.

Following the quarter, Prescient completed recruitment of patients for a higher dose level in its phase 1b basket study of PTX-100 in a mix of solid and haematological cancers.

A key milestone during the June quarter was Prescient entering a research partnering with the Peter MacCallum Cancer Centre to advance the development of its CAR-T therapy using the OmniCAR platform. Prescient will own any resulting intellectual property from this partnership.

In addition, a cell therapy enhancement program at Carina Biotech has been consolidated and is now being undertaken at Peter Mac which the company believes reflects its growing relationship with the world-renowned researcher.

Prescient spent $1.14 million on operating activities which mainly went towards admin and corporate costs, followed by research and development.

The healthcare stock ended the quarter with $16.09 million in cash.

Company shares were up 5.56 per cent and were trading at 19 cents at 11:48 am AEST.

PTX by the numbers
More From The Market Herald

" Anatara Lifesciences (ASX:ANR) expands eligibility criteria for IBS and psychological functioning trials

Anatara Lifesciences (ASX:ANR) has received ethics approval to expand eligibility criteria for its Irritable Bowel Syndrome…

" Althea (ASX:AGH) enters Irish medicinal cannabis market

Althea (ASX:AGH) has received approval from the Health Products Regulatory Authority (HPRA) for its CBD12:THC10 product…

" Apiam Animal Health (ASX:AHX) executes growth strategy with two acquisitions

Apiam Animal Health (ASX:AHX) has announced new acquisitions as part of its growth strategy to double…

" Next Science (ASX:NXS) appoints Oraderm Pharmaceuticals as BlastX distributor

Next Science (ASX:NXS) has signed a multi-year distribution agreement for the sale and distribution of its…